Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;83(6):e453-e454.
doi: 10.1016/j.jaad.2020.07.099. Epub 2020 Jul 29.

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign

Carlos Gustavo Wambier  1 , Sergio Vaño-Galván  2 , John McCoy  3 , Suraj Pai  4 , Rachita Dhurat  4 , Andy Goren  3
Affiliations
Comment

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign

Carlos Gustavo Wambier et al. J Am Acad Dermatol. 2020 Dec.
No abstract available

PubMed Disclaimer

Figures

None
Graphical abstract
Fig 1
Fig 1
The Gabrin sign. Severe AGA with an HNS score of greater than 3 in the context of COVID-19 infection is associated with worse hospital outcomes. The photograph shows a 37-year-old man hospitalized in Brazil for severe COVID-19, without comorbidities; he required a ventilator for 10 days. The bars depict outcomes of a pilot study performed in India in May 2020 among 44 men who had AGA scored with HNS. The Gabrin sign was associated with worse hospital outcomes (use of ventilator and deaths), Fisher's exact test, P = .014. All men had an HNS score of greater than 1. Only men with the Gabrin sign had worse outcomes (red and black bars). Proportions of worse outcomes increased with higher HNS scores (HNS score of 3-7, 62%; HNS score of 3v-7: 67%; and HNS score of 4-7: 75%). AGA, Androgenetic alopecia; HNS, Hamilton-Norwood scale.
Fig 2
Fig 2
Age-matched comparison of AGA of very severe baldness between the Australian 2003 data (general population) versus the Spanish 2020 data (hospitalized men with severe COVID-19). Patients with COVID-19 showed higher frequencies of very severe baldness at all age groups. The gap significantly increases after 55 years. The majority of patients hospitalized because of severe COVID-19 older than 55 years presented with very severe baldness. Very severe baldness accounted for “frontal and vertex” in the data from Severi et al and HNS score of 4 to 7 in the data from Wambier et al. More details are available via Mendeley at https://dx.doi.org/10.17632/jk63cthxbr.2. AGA, Androgenetic alopecia.
See this image and copyright information in PMC

Comment on

References

    1. Wambier C.G., Vaño-Galván S., McCoy J., et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients—the “Gabrin sign”. J Am Acad Dermatol. 2020;83:680–682. - PMC - PubMed
    1. Nanes B. Androgenetic alopecia in COVID-19: compared to what? J Am Acad Dermatol. 2020 doi: 10.1016/j.jaad.2020.06.1031. - DOI - PMC - PubMed
    1. Norwood O.T. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–1365. - PubMed
    1. Severi G., Sinclair R., Hopper J.L., English D.R., Mccredie M.R.E. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003;149(6):1207–1213. - PubMed
    1. Wambier C.G., Goren A., Vaño-Galván S., et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 doi: 10.1002/ddr.21688. - DOI - PMC - PubMed